ADAR1 Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001940272

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2025 · 201 positions · Total reported value $980.12M · Top-10 concentration 52.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.5% · 33 new · 62 cut · 48 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2025 13F filing, ADAR1 Capital Management, LLC disclosed 201 equity positions with a combined reported value of $980.12M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 52.1% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were ABVX ($114.69M), KROS ($85.26M), PTGX ($65.71M). By sector, the heaviest allocations are Health Care 78.6%, Financials 1.2%. Versus the prior quarter, allocation shifted toward Health Care (+4.3pp) and away from Other (-4.2pp).

Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 61% of names.

The largest new positions opened in Q3 2025 were IVVD ($8.11M), MTSR ($7.98M), EQ ($7.95M).

Of the 48 positions fully exited versus the prior quarter, the largest were SAGE ($6.58M), VERV ($5.27M), HLXB ($4.70M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • IVVD INVIVYD INC · $8.11M
  • MTSR METSERA INC · $7.98M
  • EQ EQUILLIUM INC · $7.95M
  • QURE UNIQURE NV · $7.78M
  • BBOT BRIDGEBIO ONCOLOGY THERAPEUT · $5.80M
  • ATAI Ataibeckley Inc CVR · $4.83M
  • UTHR UNITED THERAPEUTICS CORP DEL · $4.70M
  • XBI SPDR SERIES TRUST · $4.01M

Fully Exited (vs previous quarter)

  • SAGE SAGE THERAPEUTICS INC · prev qtr: $6.58M
  • VERV VERVE THERAPEUTICS INC · prev qtr: $5.27M
  • HLXB HELIX ACQUISITION CORP II · prev qtr: $4.70M
  • SHY ISHARES TR · prev qtr: $4.42M
  • ARDX ARDELYX INC · prev qtr: $3.59M
  • THRD THIRD HARMONIC BIO INC · prev qtr: $3.38M
  • ALEC ALECTOR INC · prev qtr: $2.41M
  • CRMD CORMEDIX INC · prev qtr: $2.16M

Insider Transactions (Form 4)

Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-11 Buy NextCure, Inc. 12,333 $5.10 SEC filing
2026-11-06 Buy NextCure, Inc. 3,662 $5.10 SEC filing
2026-11-05 Buy InMed Pharmaceuticals Inc. 2,640 $13.10 SEC filing
2026-11-05 Buy NextCure, Inc. 1,024 $5.10 SEC filing
2026-10-27 Buy NextCure, Inc. 3,553 $5.10 SEC filing
2026-10-26 Buy NextCure, Inc. 1,672 $5.03 SEC filing
2026-10-23 Buy InMed Pharmaceuticals Inc. 4 $1.32 SEC filing
2026-10-23 Buy NextCure, Inc. 5,626 $4.83 SEC filing

All insider transactions →

Fund Profile

ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-130082 (status: Approved), registered 2024-04-25
  • Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 268 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 34.2% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
  • Average position size: $6.74M

Sector Tilt

  • Health Care 86.5%
  • Financials 2.6%
  • Industrials 0.4%
  • (classified holdings cover 90% of value)

Quarterly Activity

  • Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
  • 67 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 78.6%
Financials 1.2%
Other 19.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.35M $114.69M 11.70%
11.70%
Reduce
2 5.39M $85.26M 8.70%
8.70%
Hold
3 989.18K $65.71M 6.70%
6.70%
Add
4 3.35M $50.65M 5.17%
5.17%
Add
5 337.12K $38.39M 3.92%
3.92%
Hold
6 2.24M $36.14M 3.69%
3.69%
Add
7 2.11M $31.06M 3.17%
3.17%
Add
8 45.50K $30.31M 3.09%
3.09%
Add
9 868.78K $29.44M 3.00%
3.00%
Add
10 518.92K $28.52M 2.91%
2.91%
Reduce
11 1.18M $22.13M 2.26%
2.26%
Add
12 1.47M $14.34M 1.46%
1.46%
Reduce
13 2.90M $13.18M 1.34%
1.34%
Add
14 507.77K $13.10M 1.34%
1.34%
Reduce
15 4.05M $12.90M 1.32%
1.32%
Add
16 135.59K $12.44M 1.27%
1.27%
Hold
17 866.20K $11.77M 1.20%
1.20%
Reduce
18 1.88M $11.05M 1.13%
1.13%
Reduce
19 130.00K $10.62M 1.08%
1.08%
Add
20 248.37K $10.34M 1.05%
1.05%
Add
21 1.53M $10.17M 1.04%
1.04%
Add
22 248.92K $10.03M 1.02%
1.02%
Reduce
23 2.84M $9.27M 0.95%
0.95%
Reduce
24 15.70K $8.83M 0.90%
0.90%
Add
25 133.82K $8.75M 0.89%
0.89%
Reduce
26 351.03K $8.58M 0.88%
0.88%
Add
27 5.25M $8.50M 0.87%
0.87%
Add
28 7.37M $8.11M 0.83%
0.83%
New
29 152.52K $7.98M 0.81%
0.81%
New
30 5.56M $7.95M 0.81%
0.81%
New
31 750.00K $7.92M 0.81%
0.81%
Hold
32 133.32K $7.78M 0.79%
0.79%
New
33 213.06K $7.67M 0.78%
0.78%
Add
34 815.98K $7.67M 0.78%
0.78%
Reduce
35 189.10K $7.59M 0.78%
0.78%
Reduce
36 36.34K $7.23M 0.74%
0.74%
Add
37 1.99M $7.10M 0.72%
0.72%
Reduce
38 349.81K $6.74M 0.69%
0.69%
Add
39 139.14K $6.50M 0.66%
0.66%
Add
40 501.23K $5.80M 0.59%
0.59%
New
41 51.45K $5.49M 0.56%
0.56%
Add
42 516.48K $5.48M 0.56%
0.56%
Hold
43 267.82K $5.41M 0.55%
0.55%
Reduce
44 49.57K $5.01M 0.51%
0.51%
Add
45 913.24K $4.83M 0.49%
0.49%
New
46 11.20K $4.70M 0.48%
0.48%
New
47 175.92K $4.62M 0.47%
0.47%
Add
48 405.09K $4.26M 0.43%
0.43%
Reduce
49 72.01K $4.10M 0.42%
0.42%
Add
50 40.00K $4.01M 0.41%
0.41%
New

FAQ

What did ADAR1 Capital Management, LLC buy in 2025-Q3?

In its 2025-Q3 13F filing, ADAR1 Capital Management, LLC reported 201 equity positions worth $980.12M in aggregate; its largest disclosed positions were ABVX ($114.69M), KROS ($85.26M), PTGX ($65.71M).

How large is ADAR1 Capital Management, LLC's portfolio?

ADAR1 Capital Management, LLC reported $980.12M of long equity holdings across 201 positions as of 2025-Q3. Top-10 holdings account for 52.1% of reported value.

What is ADAR1 Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/adar1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →